Journal of Modern OncologyJournal of Modern Oncology1815-14341815-1442LLC Obyedinennaya Redaktsiya29523Ingibitory tirozinkinazy EGFR v terapii 1-y linii nemelkokletochnogo raka legkogo: perekhod ot empiricheskogo podkhoda k personalizatsii lecheniyaArtamonovaE V-15122012144263109042020Copyright © 2012, Consilium Medicum2012[1. Section of Cancer Information (6/3/2011); p. 13. Int J Cancer 2010; 127 (I 12): 2893-917. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf][2. Alatar ML, Gold KA, Kim ES. Evolving treatment paradigms in non-small-cell lung cancer. Clin Oncol 2009; 12 (2): 29-43.][3. Злокачественные новообразования в России в 2010 г. (заболеваемость и смертность). Под ред. В.И.Чиссова, В.В.Старинского, Г.В.Петровой. М., 2012.][4. Kelly K, Crowley J, Bunn PA et al. Randomized phase III trial of paclitaxel plus carboplatin vs vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. JCO 2001; 19 (13): 3210-8.][5. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346 (2): 92-8.][6. Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. JCO 2002; 20 (21): 4285-91.][7. Belani CP; TAX 326 study group. Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small-cell lung cancer. Semin Oncol 2002; 29 (3 Suppl. 12): 4-9.][8. Gandara DR, Lara PN Jr, Mack P, Scagliotti GV. Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making. Clin Lung Cancer 2009; 10 (3): 148-50.][9. Wells A. EGF receptor. Int J Biochem Cell Biol 1999; 31 (6): 637-43.][10. Downward J, Yarden Y, Mayes E et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984; 307: 521-7.][11. Pavelic K, Banjac Z, Рavelic J et al. Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 1993; 13: 1133-7.][12. Arteaga CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002; 29: 3-9.][13. Salomon DS, Brandt R, Ciardiello F et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.][14. Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37: s3-8.][15. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.][16. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.][17. Mok TS. A target or demi-target. Clinical lung cancer 2010; 11 (3): 147-8.][18. Murray S, Dahabreh IJ, Linardou H et al. Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small-cell lung cancer: an analytical database. J Thorac Oncol 2008; 3: 832-9.][19. Paz-Ares L. Gefitinib - the resurrection. ESMO 2010. Ann Oncol 2010; 21 (8): 24.][20. D'Angelo S, Pietanza MC, Johnson ML et al. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. JCO 2011; 29 (15): 2066-70.][21. Моисеенко Ф.В. Частота активирующих мутаций в гене EGFR в аденокарциномах легкого, полученных от больных Северо-Западной части РФ. Автореф. дис. … канд. мед. наук. СПб., 2009.][22. Moiseyenko VM, Procenko SA, Levchenko EV et al. High efficacy of first-line gefitinib in non-asian patients with EGFR-mutated lung adenocarcinoma. Oncol 2010; 33: 231-8.][23. Zhu CQ, da Cunha Santos G, Ding K et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26: 4268-75.][24. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006; 24: 5034-42.][25. Douillard J, Hirsh V, Mok TS et al. Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small-cell lung cancer (INTEREST). J Clin Oncol 2008; 26: 424s.][26. Brugger W, Triller N, Blasinska-Morawiec M et al. Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC. J Clin Oncol 2009; 27: 411s.][27. Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. NEJM 2009; 361 (10): 958-67.][28. De Grève J. First-line erlotinib in advanced non-small-cell lung cancer (NSCLC) carrying an activating EGFR mutation: a multicenter academic phase II study in Caucasian patients (pts) (NCT 00339586) - FIELT study group. ASCO 2011. JCO 2011; 29 (15): 499. Abstr. 7597.][29. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-46.][30. Janne PA et al. Outcome of advanced NSCLC patients with EGFR exon 19 and 21 mutations treated with erlotinib alone or in combination with carboplatin/paclitaxel (CP) in CALGB 30406. 2011; WCLC. Abstr. O39.01.][31. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-57.][32. Zhou C, Wu Y, Chen G et al. Erlotinib vs chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-42.][33. Han JY, Park K, Kim SW et al. First-SIGNAL: first-line single-agent iressa vs gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. Clin Oncol 2012; 30 (10): 1122-8.][34. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harboring mutations of the epidermal growth factor receptor (WJTOG 3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11 (2): 121-8.][35. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362 (25): 2380-8.][36. Pérez-Soler R, Delord JP, Halpern A et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncolog 2005; 10: 345-56.][37. Elez E, Macarulla T, Tabernero J. Handling side-effects of targeted therapies: safety of targeted therapies in solid tumours. Ann Oncol 2008; 7: 146-52.][38. Costa EC, Taron M, Queralt C et al. Differential progression-free survival (PFS) to erlotinib according to EGFR exon 19 deletion type in non-small-cell lung cancer (NSCLC) patients (p) in the EURTAC study. ASCO 2012. Abstr. 7540.][39. Zhou C et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced ERFR mutation-positive NSCLC (OPTIMAL). Lancet Oncol 2011; 12: 735-42.][40. Zhou C, Wu Y, Chen G et al. Erlotinib vs chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG 0802): a multicentre, open-label, randomised, study. Lancet Oncol 2011; 12: 735-42.][41. Gridelli C, Ciardiello F, Feld R et al. International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) vs first-line CG followed second-line E in advanced non-small-cell lung cancer (aNSCLC): the TORCH trial. Proc ASCO 2010; JCO 2010; 28 (18): 540. Abstr. 7508.][42. Paz-Ares L, Soulieres D, Melezinec I et al. Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med 2010; 14 (1-2): 51-69.]